Complement component 3: a new paradigm in tuberculosis vaccine
نویسندگان
چکیده
منابع مشابه
A New Paradigm for Component-based Development
Hancock and Setzer [10] describe how Haskell’s monolithic IO monad can be decomposed into worlds when working in a dependently typed language, like Martin-Löf’s type theory [15]. This paper introduces the notion of world map and shows that worlds and world maps form a category with arbitrary products. The construction of the category is carried out entirely in type theory and directly implement...
متن کاملVaccine against tuberculosis: what’s new?
BACKGROUND one of the World Health Organization Millennium Development Goal is to reduce tuberculosis incidence by 2015. However, more of 8.5 million tuberculosis cases have been reported in 2011, with an increase of multidrug-resistant strains. Therefore, the World Health Organization target cannot be reach without the help of a vaccine able to limit the spread of tuberculosis. Nowadays, bacil...
متن کاملComponent-Based Software Development-A New Paradigm in Software Engineering?
Component-based software development i s associated with a shift from statement-oriented coding to system building by plugging together components. The idea is not new and some progress has been made over the past decades. Nevertheless, today's software development practice is still far away from the vision. In recent years, the term componentware has become the vogue in the software engineerin...
متن کاملStructure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition.
Undesired complement activation is a major cause of tissue injury in various pathological conditions and contributes to several immune complex diseases. Compstatin, a 13-residue peptide, is an effective inhibitor of the activation of complement component C3 and thus blocks a central and crucial step in the complement cascade. The precise binding site on C3, the structure in the bound form, and ...
متن کاملPneumococcal Conjugate Vaccine for Adults: A New Paradigm
A 13-valent pneumococcal conjugate vaccine has been studied in adults aged ≥ 50 years to compare the immune response to that induced by the 23-valent pneumococcal polysaccharide vaccine, which has been the standard of care over the past 30 years. The results demonstrate that adults, regardless of whether they are naive or previously vaccinated with the polysaccharide vaccine, have an overall su...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Review of Vaccines
سال: 2015
ISSN: 1476-0584,1744-8395
DOI: 10.1586/14760584.2016.1125294